These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6124391)

  • 1. Glucuronidation and disposition of drug glucuronides in patients with renal failure. A review.
    Verbeeck RK
    Drug Metab Dispos; 1982; 10(1):87-9. PubMed ID: 6124391
    [No Abstract]   [Full Text] [Related]  

  • 2. Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver.
    Wang M; Dickinson RG
    Drug Metab Dispos; 1998 Feb; 26(2):98-104. PubMed ID: 9456294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug metabolites in renal failure: pharmacokinetic and clinical implications.
    Verbeeck RK; Branch RA; Wilkinson GR
    Clin Pharmacokinet; 1981; 6(5):329-45. PubMed ID: 7037261
    [No Abstract]   [Full Text] [Related]  

  • 4. Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.
    Macdonald JI; Wallace SM; Mahachai V; Verbeeck RK
    Eur J Clin Pharmacol; 1992; 42(5):471-4. PubMed ID: 1606992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased body clearance of diflunisal in renal insufficiency--an alternative explanation.
    Levy G
    Br J Clin Pharmacol; 1979 Dec; 8(6):601. PubMed ID: 533584
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucuronidation of diflunisal, (-)-morphine, 4-nitrophenol, and propofol in liver microsomes of two patients with Crigler-Najjar syndrome type I.
    Brunelle FM; Raoof AA; de ville de Goyet J; Verbeeck RK
    Biopharm Drug Dispos; 1996 May; 17(4):311-7. PubMed ID: 8743402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased clearance of diflunisal in renal insufficiency--an alternative explanation.
    Faed EM
    Br J Clin Pharmacol; 1980 Aug; 10(2):185-6. PubMed ID: 7426281
    [No Abstract]   [Full Text] [Related]  

  • 8. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?
    Spahn-Langguth H; Benet LZ
    Drug Metab Rev; 1992; 24(1):5-47. PubMed ID: 1555494
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucuronidation of R- and S-ketoprofen, acetaminophen, and diflunisal by liver microsomes of adjuvant-induced arthritic rats.
    Meunier CJ; Verbeeck RK
    Drug Metab Dispos; 1999 Jan; 27(1):26-31. PubMed ID: 9884306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of polymorphic variation in drug metabolism: III. Glucuronidation and sulfation of diflunisal in man.
    Herman RJ; Loewen GR; Antosh DM; Taillon MR; Hussein S; Verbeeck RK
    Clin Invest Med; 1994 Aug; 17(4):297-307. PubMed ID: 7982293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.
    Petitpierre B; Perrin L; Rudhardt M; Herrera A; Fabre J
    Int J Clin Pharmacol; 1972 Jun; 6(2):120-4. PubMed ID: 4638970
    [No Abstract]   [Full Text] [Related]  

  • 12. Short half-life benzodiazepines.
    Greenblatt DJ; Shader RI
    Ration Drug Ther; 1984 Apr; 18(4):1-5. PubMed ID: 6150514
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of renal dysfunction on the disposition of non-steroidal anti-inflammatory drugs forming acyl-glucuronides.
    Meffin PJ
    Agents Actions Suppl; 1985; 17():85-9. PubMed ID: 3867283
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug metabolism in malnourished children.
    Mehta S; Nain CK; Sharma B; Mathur VS
    Prog Clin Biol Res; 1981; 77():739-46. PubMed ID: 6801701
    [No Abstract]   [Full Text] [Related]  

  • 15. [Concept of half-life and benzodiazepine metabolism. Critical study].
    Cano JP; Coassolo P
    Encephale; 1983; 9(4 Suppl 2):75B-80B. PubMed ID: 6144533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans.
    Mano Y; Usui T; Kamimura H
    Biopharm Drug Dispos; 2006 Sep; 27(6):267-73. PubMed ID: 16733833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic behavior of clofibrate in patients with kidney insufficiency].
    Hartlapp J; Kürten J; Klehr U; Gugler R
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1709-11. PubMed ID: 611915
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic disposition of ciramadol in rhesus monkeys and rats.
    Sisenwine SF; Tio CO; Ruelius HW
    Drug Metab Dispos; 1982; 10(2):161-7. PubMed ID: 6124403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.
    Verbeeck RK; Loewen GR; MacDonald JI; Herman RJ
    Br J Clin Pharmacol; 1990 Apr; 29(4):381-9. PubMed ID: 2328191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renal disease upon drug disposition.
    Reidenberg MM; Drayer DE
    Drug Metab Rev; 1978; 8(2):293-302. PubMed ID: 363386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.